Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary^®): Results of a Nationwide Dose Conversion Survey.

ABSTRACT:

Background

The introduction of carbidopa-levodopa extended-release (CD-LD ER) capsules (Rytary®) did not go as smoothly as expected, largely due to difficulty around dose conversion from available immediate-release (IR) levodopa (LD) formulations. The dose conversion table in the CD-LD ER prescribing information was similar to the table used in the pivotal clinical trial and is considered by many prescribing HCPs to be less than optimal. By the end of the dose conversion period in that trial, dosing in 76% of subjects was adjusted for symptom control; roughly 60% of patients required a higher dose and about half required more frequent administration than the recommended TID dosing.

Objective

The primary objective of our nationwide (US) survey was to determine the dose conver

SUBMITTER: Hauser RA 

PROVIDER: S-EPMC7914099 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature